The present invention relates to a novel drug candidate having a potential for universal therapy of allergy and asthma. The invention provides a Fab (antibody fragment), having the following characteristics:

a) inhibits the IgE-FcRI interaction;

b) binds to free and cell-bound IgE; and

c) is non-anaphylactic.